Literature DB >> 33590406

Prophylactic strategies to control chikungunya virus infection.

Friederike I L Hucke1, Malena Bestehorn-Willmann1, Joachim J Bugert2.   

Abstract

Chikungunya virus (CHIKV) is a (re)emerging arbovirus and the causative agent of chikungunya fever. In recent years, CHIKV was responsible for a series of outbreaks, some of which had serious economic and public health impacts in the affected regions. So far, no CHIKV-specific antiviral therapy or vaccine has been approved. This review gives a brief summary on CHIKV epidemiology, spread, infection and diagnosis. It furthermore deals with the strategies against emerging diseases, drug development and the possibilities of testing antivirals against CHIKV in vitro and in vivo. With our review, we hope to provide the latest information on CHIKV, disease manifestation, as well as on the current state of CHIKV vaccine development and post-exposure therapy.

Entities:  

Keywords:  Antiviral design; Antiviral testing; CHIKV epidemiology; Monoclonal antibodies; Vaccines

Mesh:

Substances:

Year:  2021        PMID: 33590406      PMCID: PMC7883954          DOI: 10.1007/s11262-020-01820-x

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.332


  132 in total

1.  Cellular IMPDH enzyme activity is a potential target for the inhibition of Chikungunya virus replication and virus induced apoptosis in cultured mammalian cells.

Authors:  M Khan; R Dhanwani; I K Patro; P V L Rao; M M Parida
Journal:  Antiviral Res       Date:  2010-11-09       Impact factor: 5.970

2.  Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus.

Authors:  Scott A Smith; Laurie A Silva; Julie M Fox; Andrew I Flyak; Nurgun Kose; Gopal Sapparapu; Solomiia Khomandiak; Solomiia Khomadiak; Alison W Ashbrook; Kristen M Kahle; Rachel H Fong; Sherri Swayne; Benjamin J Doranz; Charles E McGee; Mark T Heise; Pankaj Pal; James D Brien; S Kyle Austin; Michael S Diamond; Terence S Dermody; James E Crowe
Journal:  Cell Host Microbe       Date:  2015-07-08       Impact factor: 21.023

3.  Sterile-insect methods for control of mosquito-borne diseases: an analysis.

Authors:  Luke Alphey; Mark Benedict; Romeo Bellini; Gary G Clark; David A Dame; Mike W Service; Stephen L Dobson
Journal:  Vector Borne Zoonotic Dis       Date:  2010-04       Impact factor: 2.133

4.  Gene drive: progress and prospects.

Authors:  N Wedell; T A R Price; A K Lindholm
Journal:  Proc Biol Sci       Date:  2019-12-18       Impact factor: 5.349

5.  Aedes Aegypti saliva enhances chikungunya virus replication in human skin fibroblasts via inhibition of the type I interferon signaling pathway.

Authors:  Sineewanlaya Wichit; Fodé Diop; Rodolphe Hamel; Loïc Talignani; Pauline Ferraris; Sylvie Cornelie; Florian Liegeois; Frédéric Thomas; Hans Yssel; Dorothée Missé
Journal:  Infect Genet Evol       Date:  2017-09-01       Impact factor: 3.342

6.  A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection.

Authors:  Wataru Akahata; Zhi-Yong Yang; Hanne Andersen; Siyang Sun; Heather A Holdaway; Wing-Pui Kong; Mark G Lewis; Stephen Higgs; Michael G Rossmann; Srinivas Rao; Gary J Nabel
Journal:  Nat Med       Date:  2010-01-28       Impact factor: 53.440

7.  A Virus-Like Particle Vaccine Elicits Broad Neutralizing Antibody Responses in Humans to All Chikungunya Virus Genotypes.

Authors:  Leslie Goo; Kimberly A Dowd; Tsai-Yu Lin; John R Mascola; Barney S Graham; Julie E Ledgerwood; Theodore C Pierson
Journal:  J Infect Dis       Date:  2016-09-21       Impact factor: 5.226

8.  Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes.

Authors:  Pankaj Pal; Julie M Fox; David W Hawman; Yan-Jang S Huang; Ilhem Messaoudi; Craig Kreklywich; Michael Denton; Alfred W Legasse; Patricia P Smith; Syd Johnson; Michael K Axthelm; Dana L Vanlandingham; Daniel N Streblow; Stephen Higgs; Thomas E Morrison; Michael S Diamond
Journal:  J Virol       Date:  2014-05-14       Impact factor: 5.103

Review 9.  Chikungunya as a paradigm for emerging viral diseases: Evaluating disease impact and hurdles to vaccine development.

Authors:  Giovanni Rezza; Scott C Weaver
Journal:  PLoS Negl Trop Dis       Date:  2019-01-17

10.  Prophylaxis and therapy for Chikungunya virus infection.

Authors:  Thérèse Couderc; Nassirah Khandoudi; Marc Grandadam; Catherine Visse; Nicolas Gangneux; Sébastien Bagot; Jean-François Prost; Marc Lecuit
Journal:  J Infect Dis       Date:  2009-08-15       Impact factor: 5.226

View more
  1 in total

1.  CHIKV strains Brazil (wt) and Ross (lab-adapted) differ with regard to cell host range and antiviral sensitivity and show CPE in human glioblastoma cell lines U138 and U251.

Authors:  Friederike I L Hucke; Malena Bestehorn-Willmann; Marcella Bassetto; Andrea Brancale; Paola Zanetta; Joachim J Bugert
Journal:  Virus Genes       Date:  2022-03-26       Impact factor: 2.198

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.